Literature DB >> 23600369

Overexpression of CD39 protects in a mouse model of preeclampsia.

Jennifer L McRae1, Prudence A Russell, Joanne Sj Chia, Karen M Dwyer.   

Abstract

CD39 (NTPDase1), a critical immune and vascular ecto-nucleotidase, hydrolyses pro-inflammatory and pro-thrombotic nucleotides (adenosine-5'-triphosphate (ATP) and adenosine diphosphate) to adenosine. In humans, CD39 is the dominant ecto-nucleotidase in placental trophoblastic tissues and modulates ATP-dependent trophoblastic functions. CD39 is an integral component of regulatory T cells (Treg), which are central to immunological tolerance and maintenance of normal pregnancy. We examined the impact of CD39 overexpression in a mouse model of preeclampsia. Matings were performed between virginal BALB/c female (wild-type (WT) or CD39 transgenic (CD39TG)) and C57BL/6 male mice. On days 10 and 12 of pregnancy BALB/c Th1-polarized cells were injected. Systolic blood pressure (SBP) was measured throughout pregnancy. Mice were sacrificed at day 15 of pregnancy. Following transfer of Th1-polarized cells, SBP of pregnant WT mice increased (118 ± 3 mmHg to 142 ± 5 mmHg). Although ultrastructural changes were evident in the kidney this was not accompanied by significant proteinuria. SBP remained unchanged (115 ± 2 mmHg to 114 ± 3 mmHg) in pregnant CD39TG mice without evidence of renal lesions. We conclude that gestational hypertension can be induced in mice following transfer of maternally derived Th1-polarized cells and that overexpression of CD39 is protective in this model.
© 2013 The Authors. Nephrology © 2013 Asian Pacific Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23600369     DOI: 10.1111/nep.12058

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  7 in total

1.  Splenocyte transfer exacerbates salt-sensitive hypertension in rats.

Authors:  Daniel J Fehrenbach; John Henry Dasinger; Hayley Lund; Jeylan Zemaj; David L Mattson
Journal:  Exp Physiol       Date:  2020-03-17       Impact factor: 2.969

2.  Loss of vascular expression of nucleoside triphosphate diphosphohydrolase-1/CD39 in hypertension.

Authors:  Charlotte Roy; Julie Tabiasco; Antoine Caillon; Yves Delneste; Jean Merot; Julie Favre; Anne Laure Guihot; Ludovic Martin; Daniele C Nascimento; Bernhard Ryffel; Simon C Robson; Jean Sévigny; Daniel Henrion; Gilles Kauffenstein
Journal:  Purinergic Signal       Date:  2017-12-13       Impact factor: 3.765

3.  Low-dose aspirin therapy improves decidual arteriopathy in pregnant women with a history of preeclampsia.

Authors:  Kayo Tomimori-Gi; Shinji Katsuragi; Yuki Kodama; Naoshi Yamada; Hiroshi Sameshima; Kazunari Maekawa; Atsushi Yamashita; Toshihiro Gi; Yuichiro Sato
Journal:  Virchows Arch       Date:  2022-07-30       Impact factor: 4.535

Review 4.  CD39 in the development and progression of pulmonary arterial hypertension.

Authors:  Abbey Willcox; Natasha Ting Lee; Harshal H Nandurkar; Maithili Sashindranath
Journal:  Purinergic Signal       Date:  2022-08-10       Impact factor: 3.950

5.  Evaluation of CD39, CD73, HIF-1α, and their related miRNAs expression in decidua of preeclampsia cases compared to healthy pregnant women.

Authors:  Yousef Yousefzadeh; Mohammad Sadegh Soltani-Zangbar; Ladan Kalafi; Ali Tarbiat; Sima Shahmohammadi Farid; Leili Aghebati-Maleki; Forough Parhizkar; Shahla Danaii; Simin Taghavi; Farhad Jadidi-Niaragh; Hossein Samadi Kafil; Ata Mahmoodpoor; Javad Ahmadian Heris; Mohammad Hojjat-Farsangi; Mehdi Yousefi
Journal:  Mol Biol Rep       Date:  2022-09-01       Impact factor: 2.742

Review 6.  CD39: Interface between vascular thrombosis and inflammation.

Authors:  Yogendra M Kanthi; Nadia R Sutton; David J Pinsky
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

Review 7.  The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases.

Authors:  Margarete Dulce Bagatini; Alessandra Antunes Dos Santos; Andréia Machado Cardoso; Aline Mânica; Cristina Ruedell Reschke; Fabiano Barbosa Carvalho
Journal:  J Immunol Res       Date:  2018-08-12       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.